NATCO Pharma LimitedNSE: NATCOPHARM

Press Release Nov 09 2022

· Issued by NATCO Pharma Limited

Filed with NSE · · 2 pages · English

Summary by 6ix AI

The product is available in multiple strengths and was launched in partnership with Juno Pharmaceuticals Pty Ltd. Pomalidomide is used for treating Multiple Myeloma and Kaposi Sarcoma, with significant sales reported in the Australian market for the previous year.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

NATCO Pharma Limited on 6ix

In the deck

Earlier from NATCO Pharma

Later from NATCO Pharma

All NATCO Pharma news releases